Cronos Australia Ltd. (AU:VIT)
ASX:VIT
Want to see AU:VIT full AI Analyst Report?
Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Select Model
Select Model
Rating:56Neutral
Price Target:
AU$0.03
▼(-48.33% Downside)
Action:Reiterated
Date:06/18/26
The score is mainly held back by weak technicals (price below all major moving averages and negative MACD). Financial performance is moderate with a strong balance sheet but challenged by declining revenue growth and poor cash generation metrics. Valuation is mixed: a high dividend yield helps, while the P/E remains relatively high.
Positive Factors
Balance sheet strength
Low leverage and a high equity ratio give Cronos Australia durable financial flexibility. A debt-to-equity of 0.25 and 63.85% equity base reduce refinancing and solvency risk, enabling the company to fund operations, pursue opportunities, or withstand sector cyclical shocks without heavy external financing.
Negative Factors
Weak cash generation
Severely negative free cash flow growth and a low operating-cash-flow-to-net-income ratio indicate poor cash conversion. This reduces capacity to fund capex, pay dividends sustainably, or absorb shocks without external funding, raising medium-term liquidity and financing risks for operations and strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Low leverage and a high equity ratio give Cronos Australia durable financial flexibility. A debt-to-equity of 0.25 and 63.85% equity base reduce refinancing and solvency risk, enabling the company to fund operations, pursue opportunities, or withstand sector cyclical shocks without heavy external financing.
Read all positive factors
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.21M
Dividend Yield3.28%
Average Volume (3M)228.84K
Price to Earnings (P/E)25.8
Beta (1Y)1.52
Revenue Growth2.11%
EPS Growth-64.71%
CountryAU
Employees72
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cronos Australia Ltd. Business Overview & Revenue Model
Company Description
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanVie...
How the Company Makes Money
null...
Cronos Australia Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 129.24M | 124.04M | 123.87M | 117.34M | 66.99M | 21.71M |
| Gross Profit | 19.87M | 33.75M | 34.22M | 25.96M | 25.43M | 3.19M |
| EBITDA | 4.15M | 5.64M | 7.08M | 21.08M | 10.87M | 2.12M |
| Net Income | 784.13K | 3.32M | 3.51M | 13.81M | 6.05M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 76.85M | 75.49M | 71.28M | 46.90M | 42.87M | 12.69M |
| Cash, Cash Equivalents and Short-Term Investments | 6.10M | 7.58M | 11.35M | 18.85M | 16.08M | 9.47M |
| Total Debt | 17.34M | 11.97M | 11.02M | 1.71M | 5.06M | 718.02K |
| Total Liabilities | 31.49M | 27.89M | 32.84M | 11.99M | 16.79M | 3.47M |
| Stockholders Equity | 46.11M | 48.20M | 38.78M | 34.98M | 26.10M | 9.30M |
Cash Flow | ||||||
| Free Cash Flow | 1.38M | 2.58M | 6.21M | 8.78M | 13.13M | 1.01M |
| Operating Cash Flow | 1.48M | 2.67M | 7.00M | 9.71M | 13.50M | 1.07M |
| Investing Cash Flow | -4.95M | -13.87M | -13.20M | -837.72K | 2.00M | -160.69K |
| Financing Cash Flow | 2.18M | 7.43M | -1.30M | -6.10M | -1.50M | -262.03K |
Cronos Australia Ltd. Technical Analysis
Negative
0.06
Price Trends
0.04
Negative
0.04
Negative
0.05
Negative
Market Momentum
>-0.01
Negative
2.37
Positive
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.04, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 2.37 is Positive, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.
Cronos Australia Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$20.21M | 25.77 | 1.66% | 3.28% | 2.11% | -64.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$66.42M | 2.83 | 10.34% | ― | 15.21% | -141.82% | |
49 Neutral | AU$2.48M | -0.35 | -76.30% | ― | 3.64% | -23.56% | |
47 Neutral | AU$8.75M | -6.68 | 404.65% | ― | 67.74% | 78.79% | |
39 Underperform | AU$6.64M | 0.23 | 93.89% | ― | -29.95% | ― |
* Healthcare Sector Average
AU:VIT
Cronos Australia Ltd.
0.03
-0.03
-50.00%
AU:EXL
Elixinol Wellness
0.02
<0.01
15.38%
AU:CAN
Cann Group
0.01
>-0.01
-16.67%
AU:EPN
Epsilon Healthcare Limited
0.02
>-0.01
-8.33%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.02
-19.00%
Cronos Australia Ltd. Corporate Events
Vitura installs interim CFO as CEO launches finance leadership overhaul
Jun 4, 2026
Vitura Health has appointed former long-serving finance chief Tom Howitt as interim CFO following the resignation of Andrew Cook, who departed during his probationary period to pursue an external senior role aligned with his long-term career goals...
Vitura Health locks in $2.7m cost savings as growth initiatives gather pace
Apr 27, 2026
Vitura Health has outlined a business transformation that combines growth initiatives with a reset of its cost base, aiming to strengthen its position in digital health and therapeutic product distribution. The company is leveraging its Canview pl...
Vitura’s Doctors on Demand Hits 1 Million Consultations and Turns Profitable
Apr 20, 2026
Vitura Health’s Doctors on Demand telehealth service has surpassed 1 million consultations since the start of FY2024, underlining the scale and utilisation of its 24/7 virtual GP platform. The doctor network has expanded from about 200 to mo...
Vitura Health Director Gerard Fogarty AO Steps Down with Minimal Shareholdings
Apr 7, 2026
Vitura Health Limited has announced that director Gerard Fogarty AO has ceased to be a director of the company as of 7 April 2026, with no securities held in his own name at the time of his departure. His indirect interest in the company is limite...
Vitura Health director Gerard Fogarty resigns as company reshapes advisory leadership
Apr 7, 2026
Vitura Health Limited has announced the resignation of Non-Executive Director Gerard Fogarty, effective 7 April 2026, with the board to consider a new chair for its Industry Advisory Group after his departure. Independent chair Robert Iervasi than...
Vitura Health names Justin James as new CEO to drive next phase of digital health growth
Apr 2, 2026
Vitura Health has appointed experienced healthcare executive Justin James as Chief Executive Officer, effective 1 June 2026, as it seeks to accelerate its transformation in digital health and emerging therapies. James, formerly CEO of Health Insur...
Vitura Health Options Lapse, Trimming Future Equity Overhang
Mar 29, 2026
Vitura Health Limited has confirmed the lapse of 4,503,169 listed options, each exercisable at $0.2415 and due to expire on 31 August 2031, which have now ceased following expiry without being exercised. The cessation of these options slightly sim...
Cortexa Builds MDMA Supply Leadership as Australian Psychedelic Market Expands
Mar 22, 2026
Melbourne-based Cortexa, a 50/50 joint venture between Vitura Health and PharmAla Biotech, is a leading Australian supplier of psychedelic medicines focused on MDMA for regulated clinical use. Its products support local clinical research and patie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.